FAM
DSGN icon

Fred Alger Management’s Design Therapeutics DSGN Stock Holding History

Fred Alger Management’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-6,578
Closed -$92K – 529
2022
Q2 		$92K Buy
+6,578
New +$88.9K ﹤0.01% 441

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fred Alger Management's DSGN Position: Q3 2022 in Review

Fred Alger Management sold out of Design Therapeutics (DSGN) in Q3 2022, closing a stake of 6,578 shares — an estimated $92K sold.

Fred Alger Management first reported a position in DSGN in Q2 2022 and held it in 1 quarter. The position peaked at $92K in Q2 2022. 79 funds tracked by Wall St. Rank hold DSGN as of Q3 2022.

  • Fred Alger Management reported no remaining Design Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Fred Alger Management sold 6,578 Design Therapeutics shares in Q3 2022, an estimated $92K.
  • Fred Alger Management first reported a position in Design Therapeutics in Q2 2022 and held it in 1 quarter.
  • Fred Alger Management's Design Therapeutics position peaked at $92K in Q2 2022.
  • 79 funds tracked by Wall St. Rank held Design Therapeutics as of Q3 2022.

Based on Fred Alger Management's 13F filing for Q3 2022, filed 15 Nov 2022.